Depo-Provera meningioma cases: what to do before the first bellwether

A Depo-Provera claim usually starts in a very ordinary place: a
woman trying to piece together medical records from years of birth-
control shots.

That part is not glamorous. It is also the part that can make or
break a review.

The federal litigation is now MDL No. 3140, In re: Depo-Provera
(Depot Medroxyprogesterone Acetate) Products Liability Litigation.
The Judicial Panel on Multidistrict Litigation's July 1, 2026 docket
report lists the case in the Northern District of Florida before
Judge M. Casey Rodgers, under 3:25-md-3140.

That does not mean every person is in one big class action. MDLs do
not work that way. Your medical history still matters. Your
injection dates matter. Your diagnosis and treatment matter.

The cases are about meningioma, a tumor that grows from the
membranes around the brain and spinal cord. Some people hear the
word "benign" and think it means minor. Often it does not. Depending
on where the tumor sits, a meningioma can mean headaches, vision
problems, hearing changes, seizures, balance issues, surgery,
radiation, or years of follow-up scans.

The drug at issue is depot medroxyprogesterone acetate, the hormone
in Depo-Provera and some generic injections. Plaintiffs say extended
exposure raised the risk of intracranial meningioma and that the
warnings did not say enough, soon enough.

One study comes up again and again. In 2024, BMJ published a French
national case-control study involving 18,061 women who had
intracranial surgery for meningioma and 90,305 matched controls. For
injectable medroxyprogesterone acetate, the authors reported an odds
ratio of 5.55, with a 95% confidence interval of 2.27 to 13.56. They
also reported that the excess risk was linked to prolonged use,
meaning one year or more.

A study is not a verdict. It is not a promise. But it is one of the
reasons these claims have drawn serious attention.

There has also been movement on the label. Pfizer's current U.S.
prescribing information for Depo-Provera CI lists a recent major
change for "Warnings and Precautions, Meningioma" dated December

The same label says Depo-Provera CI is not recommended as a

birth-control method for longer than two years unless other options
are considered inadequate.

For people looking back at old shots, dates matter more than they
may realize. A review may turn on when the injections started, how
long they continued, which product was used, when symptoms began,
and when imaging first showed a tumor.

The court schedule is another reason to get organized now. Daubert
hearings were scheduled for June 24 through June 26, 2026. That is
the court's process for deciding which expert opinions are reliable
enough to be heard by a jury. The first bellwether trial window has
been reported for December 7 through December 14, 2026.

Bellwether trials are not magic. They do not decide everyone's case.
They do, however, put real evidence in front of a real jury. Both
sides pay attention to what happens.

If you are trying to figure out whether your history should be
reviewed, start with a timeline. Write down the first shot you
remember, the last shot, the clinic or pharmacy, the first symptom
that led to imaging, the date of diagnosis, and the treatment plan.

Then look for records. OB-GYN records. County clinic records.
Pharmacy printouts. Insurance claims. MRI and CT reports.
Neurosurgery notes. Pathology reports if surgery happened. Radiation
records if radiation happened. Follow-up scan reports. Anything
showing the shot and anything showing the meningioma.

Do not panic if you are missing pieces. Many people are. Older
records are scattered, especially when injections were given every
three months over several years. The point is to start before a
deadline or court milestone forces everyone to hurry.

A few questions come up a lot.

Do you need surgery to ask about a case? Not always. Some
meningiomas are monitored. Others are removed or treated with
radiation. The details matter.

Do generic injections count? They may. The exact product and
manufacturer still need to be checked.

Is an older diagnosis too late? Maybe, maybe not. Deadlines depend
on state law and the facts. Guessing is risky.

If you or a family member used Depo-Provera or depot
medroxyprogesterone acetate and later developed a meningioma, Mass
Tort America can help you understand what records a lawyer will want
to review.

This article is attorney advertising and general information only.
It is not medical advice, and it is not legal advice for your
specific situation. Contacting Mass Tort America does not create an
attorney-client relationship unless a written agreement is signed.
No result is guaranteed.